Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Development of Dermatomyositis after Pfizer BioNTeh COVID-19 Vaccine: A Case Report

Author(s): Imen Aouintia, Wiem Daly*, Ghozlane Lakhoua, Widd Kaabi, Ons Charfi, Sana Debbeche, Sarrah Kastalli, Ahmed Zaiem and Sihem El Aidli

Volume 19, Issue 2, 2024

Published on: 20 July, 2023

Page: [306 - 308] Pages: 3

DOI: 10.2174/1574886318666230614164607

Price: $65

Abstract

Introduction: The Coronavirus Disease 2019 (COVID-19) pandemic led to the fast development of vaccines, which is considered a medical advance in healthcare. With the extensive vaccination campaign performed worldwide, many adverse events following immunization (AEFI) were reported. Most of them were flu-like symptoms, mild and self-limiting. However, serious adverse events, such as dermatomyositis (DM), an idiopathic autoimmune connective tissue disease, have also been reported.

Case Presentation: In this report, we describe a case of skin erythema, edema, and diffuse myalgia attributed at first to Pfizer BioNTeh, COVID-19 vaccination, given the temporal relationship and the absence of significant medical history. The causality assessment score was I1B2. However, after completing the etiological assessment, an invasive breast carcinoma was identified, and we retained the diagnosis of paraneoplastic DM.

Conclusion: This study underlines the importance of completing the etiological assessment before attributing any adverse reaction to vaccination to maintain optimal patient care.

« Previous Next »
[1]
Aimo C, Mariotti EB, Corrà A, et al. Lymphedema of the arm after COVID-19 vaccination in a patient with hidden breast cancer and paraneoplastic dermatomyositis. Vaccines 2022; 10(8): 1219.
[http://dx.doi.org/10.3390/vaccines10081219] [PMID: 36016107]
[2]
Gouda W, Albasri A, Alsaqabi F, Al Sabah HY, Alkandari M, Abdelnaby H. Dermatomyositis following BNT162b2 mRNA COVID-19 vaccination. J Korean Med Sci 2022; 37(5): e32.
[http://dx.doi.org/10.3346/jkms.2022.37.e32] [PMID: 35132838]
[3]
Holzer MT, Krusche M, Ruffer N, et al. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: A case-based review. Rheumatol Int 2022; 42(12): 2267-76.
[http://dx.doi.org/10.1007/s00296-022-05176-3] [PMID: 35939078]
[4]
Regional Pharmacovigilance Center French method of drug imputability, known as the Bégaud method 2014. Available from: https://pharmacovigilance-npdc.fr/enseignement-formation-pharmacologie/imputabilite-medicamenteuse-begaud/ (Accessed 10 Dec 2022).
[5]
Hendren E, Vinik O, Faragalla H, Haq R. Breast cancer and dermatomyositis: A case study and literature review. Curr Oncol 2017; 24(5): 429-33.
[http://dx.doi.org/10.3747/co.24.3696] [PMID: 29089813]
[6]
Hu T, Vinik O. Dermatomyositis and malignancy. Can Fam Physician 2019; 65(6): 409-11.
[PMID: 31189628]
[7]
Ziani FZ, Brahmi SA, Najib R, et al. Paraneoplastic dermatomyositis revealing an undifferentiated carcinoma of the nasopharynx: About a case. Pan Afr Med J 2016; 24: 29.
[http://dx.doi.org/10.11604/pamj.2016.24.29.4822] [PMID: 27583093]
[8]
Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis and follow-up implications: A Scottish population-based cohort study. Br J Cancer 2001; 85(1): 41-5.
[http://dx.doi.org/10.1054/bjoc.2001.1699] [PMID: 11437400]
[9]
Marzęcka M, Niemczyk A, Rudnicka L. Autoantibody markers of increased risk of malignancy in patients with dermatomyositis. Clin Rev Allergy Immunol 2022; 63(2): 289-96.
[http://dx.doi.org/10.1007/s12016-022-08922-4] [PMID: 35147864]
[10]
Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 2019; 101: 48-55.
[http://dx.doi.org/10.1016/j.jaut.2019.04.001] [PMID: 30992170]
[11]
Bax CE, Maddukuri S, Ravishankar A, Pappas-Taffer L, Werth VP. Environmental triggers of dermatomyositis: A narrative [review] Ann Transl Med 2021; 9(5): 434.
[http://dx.doi.org/10.21037/atm-20-3719]
[12]
Venkateswaran K, Aw DCW, Huang J, Angkodjojo S. Dermatomyositis following COVID‐19 vaccination. Dermatol Ther 2022; 35(6): e15479.
[http://dx.doi.org/10.1111/dth.15479] [PMID: 35355380]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy